Evidence map›Paper›PMID 29313083›Full record

ReviewDer Pathologe2018

[Neuroendocrine neoplasms of the head and neck].

B Konukiewitz, A Agaimy, W Weichert, G Klöppel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Pathologe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. [Surgical treatment options for cervical paragangliomas].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2019
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

B KonukiewitzInstitut für Pathologie, Technische Universität München, Trogerstr. 18, 81675, München, Deutschland. b.konukiewitz@tum.de.
A AgaimyInstitut für Pathologie, Universitätsklinikum Erlangen, Erlangen, Deutschland.
W WeichertInstitut für Pathologie, Technische Universität München, Trogerstr. 18, 81675, München, Deutschland.
G KlöppelInstitut für Pathologie, Technische Universität München, Trogerstr. 18, 81675, München, Deutschland.
Technical University of Munich · DEUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Common to all neuroendocrine neoplasms (NENs), irrespective of their site of origin, is the expression of synaptophysin and chromogranin A. NENs of the head and neck region derive either from epithelial or neural/neuroectodermal tissues. The epithelial-type NENs express cytokeratins and include the well-differentiated typical and atypical carcinoids (also called low- and intermediate-grade neuroendocrine carcinomas by WHO), the poorly differentiated high-grade neuroendocrine carcinomas of small and large cell type and the mixed neuroendocrine-nonneuroendocrine neoplasms. The neural-neuroectodermal-type NENs comprise olfactory neuroblastoma and paraganglioma, each of them with distinct clinicopathological characteristics. Olfactory neuroblastomas show a spectrum of histologic differentiation and are prognostically classified by Hyams grading. Paragangliomas often occur multiple and show a familial background. Most head and neck NENs occur in the upper respiratory system. Their diagnosis follows the general guidelines for NENs, focusing on immunohistochemical profiling. Molecular examinations are so far only required in individual cases.

Indexed as

Carcinoid TumorHead and Neck NeoplasmsLung NeoplasmsNeuroendocrine TumorsChromogranin AHumansChromogranin ACarcinoidNeuroendocrine carcinomaNeuroendocrine tumorOlfactory neuroblastomaParaganglioma

Identifiers

PMID29313083
OpenAlexW2784206497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.